Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of methotrexate + temozolomide versus methotrexate + procarbazine + vincristine + cytarabine in elderly patients with primary central nervous system lymphoma
2006-006084-23Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of methotrexate, temozolomide, procarbazine, vincristine and cytarabine in primary central nervous system lymphoma (PCNSL) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: 1-year progression-free survival. Started Mar 2007; status: active.
02
Drugs
methotrexatetemozolomideprocarbazinevincristinecytarabine
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on 2006-006084-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006084-23.